首页> 外文期刊>Frontiers in Pharmacology >Wedelolactone Enhances Osteoblastogenesis but Inhibits Osteoclastogenesis through Sema3A/NRP1/PlexinA1 Pathway
【24h】

Wedelolactone Enhances Osteoblastogenesis but Inhibits Osteoclastogenesis through Sema3A/NRP1/PlexinA1 Pathway

机译:Wedelolactone通过Sema3A / NRP1 / PlexinA1途径增强成骨细胞生成但抑制成骨细胞生成

获取原文
           

摘要

Bone remodeling balance is maintained by tight coupling of osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Thus, agents with the capacity to regulate osteoblastogenesis and osteoclastogenesis have been investigated for therapy of bone-related diseases such as osteoporosis. In this study, we found that wedelolactone, a compound isolated from Ecliptae herba , and a 9-day incubation fraction of conditioned media obtained from wedelolactone-treated bone marrow mesenchymal stem cell (BMSC) significantly inhibited tartrate-resistant acid phosphatase (TRAP) activity in RANKL-stimulated osteoclastic RAW264.7 cells. Addition of the semaphorin 3A (Sema3A) antibody to the conditioned media partially blocked the medium’s inhibitory effects on the RAW264.7 cells. In BMSC, mRNA expression of Sema3A increased in the presence of different wedelolactone concentrations. Blocking Sema3A activity with its antibody reversed wedelolactone-induced alkaline phosphatase activity in BMSC and concurrently enhanced wedelolactone-reduced TRAP activity in osteoclastic RAW264.7 cells. Moreover, in BMSC, wedelolactone enhanced binding of Sema3A with cell-surface receptors, including neuropilin (NRP)1 and plexinA1. Furthermore, nuclear accumulation of β-catenin, a transcription factor acting downstream of wedelolactone-induced Sema3A signaling, was blocked by the Sema3A antibody. In osteoclastic RAW264.7 cells, conditioned media and wedelolactone promoted the formation of plexin A1-NRP1, but conditioned media also caused the sequestration of the plexin A1-DNAX-activating protein 12 (DAP12) complex and suppressed the phosphorylation of phospholipase C (PLC)γ2. These data suggest that wedelolactone promoted osteoblastogenesis through production of Sema3A, thus inducing the formation of a Sema3A-plexinA1-Nrp1 complex and β-catenin activation. In osteoclastic RAW264.7 cells, wedelolactone inhibited osteoclastogenesis through sequestration of the plexinA1-DAP12 complex, induced the formation of plexinA1-Nrp1 complex, and suppressed PLCγ2 activation.
机译:通过成骨细胞介导的骨形成和破骨细胞介导的骨吸收的紧密结合来维持骨重塑平衡。因此,已经研究了具有调节成骨细胞生成和破骨细胞生成能力的药物以治疗骨相关疾病,例如骨质疏松症。在这项研究中,我们发现韦德洛内酯,一种分离自草木科的化合物,以及从韦德洛内酯处理过的骨髓间充质干细胞(BMSC)获得的条件培养基的9天温育级分显着抑制了酒石酸耐药性酸性磷酸酶(TRAP)的活性。在RANKL刺激的破骨细胞RAW264.7细胞中。在条件培养基中添加Semaphorin 3A(Sema3A)抗体可部分阻止该培养基对RAW264.7细胞的抑制作用。在骨髓间充质干细胞中,在不同的韦氏内酯浓度下,Sema3A的mRNA表达增加。用其抗体阻断Sema3A活性可逆转骨髓间充质干细胞中wedelolactone诱导的碱性磷酸酶活性,并同时增强破骨细胞RAW264.7细胞中wedelolactone降低的TRAP活性。此外,在BMSC中,维地内酯增强了Sema3A与细胞表面受体(包括神经纤维蛋白(NRP)1和plexinA1)的结合。此外,Sema3A抗体阻止了β-catenin的核积累,β-catenin是一种作用于wedelolactone诱导的Sema3A信号传导下游的转录因子。在破骨细胞RAW264.7细胞中,条件培养基和wedelolactone促进了plexin A1-NRP1的形成,但条件培养基也导致螯合plexin A1-DNAX激活蛋白12(DAP12)复合物并抑制了磷脂酶C(PLC)的磷酸化。 )γ2。这些数据表明,Wedelolactone通过产生Sema3A促进成骨细胞生成,从而诱导Sema3A-plexinA1-Nrp1复合物的形成和β-连环蛋白的活化。在破骨细胞RAW264.7细胞中,维地内酯通过螯合plexinA1-DAP12复合物抑制破骨细胞生成,诱导plexinA1-Nrp1复合物形成,并抑制PLCγ2活化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号